GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>Pegasys and PegIntron have >95% market share. That of course means the non-pegylated IF-alphas have <5% market share. Could be well below 5% market share.<

You must be thinking of the U.S. market only. Worldwide, in the most recent quarter Intron-A sold at a $240M annual run rate and had a 10% share of the IFN-alpha market. (Pegasys had a 54% share and Peg-Intron had 36%.)

http://www.schering-plough.com/schering_plough/news/release.jsp?releaseID=987273
http://www.roche.com/mr1q07e.pdf

In any case, the main point is that $240M per year is not a trivial revenue stream for an FoB maker to pursue—provided that the FoB is substitutable for the original drug and doesn’t have to be actively marketed. Regards, Dew